Feature | May 20, 2015

Botox Injections Help Prevent Atrial Fibrillation After Cardiac Surgery

Study finds botulinum toxin injections in epicardial fat pads reduce AF risk immediately following surgery and after one year of follow-up

botox, atrial fibrillation, cardiac surgery, HRS

May 20, 2015 — A study presented at Heart Rhythm 2015 found that botulinum toxin (botox) injections into epicardial fat pads during coronary artery bypass graft (CABG) surgery can be beneficial for the patient. The injection not only reduces the incidence of post-operative atrial fibrillation (AF), but also provides substantial AF suppression after one year.

Heart Rhythm 2015 is the Heart Rhythm Society’s 36th annual scientific sessions, May 13-16 in Boston.  

AF is the most common arrhythmia complicating cardiac surgery and occurs in approximately 30-40 percent of patients undergoing CABG surgery. CABG is the most common type of open-heart surgery in the United States and improves blood flow to the heart to treat people with coronary heart disease. Patients who develop AF after cardiac surgery are at an increased risk of stroke and congestive heart failure.

The prospective, double-blind study randomized 60 patients with a history of paroxysmal AF undergoing CABG to receive either botox injections or a saline placebo injection during surgery. Patients were followed for one year to assess maintenance of sinus rhythm using an implantable loop recorder. All patients in both groups had successful epicardial fat pad injections without complications and with minimal additional surgery time. 

The incidence of early postoperative AF within 30 days after surgery was two patients (7 percent) in the botox group compared to nine patients (30 percent) in the placebo group. Between the 30-day period and up to the 12-month follow-up examination, seven of the 30 patients in the placebo group (27 percent) had recurrent AF, while no patients in the botox group (0 percent) experienced recurrent AF. Further, there were no complications observed during the one year follow-up. 

“Currently, there are no therapies available to reduce AF after open heart surgery, so the study results are very promising and help fulfill an unmet need in cardiology care,” said lead author Evgeny Pokushalov, M.D., Ph.D., State Research Institute of Circulation Pathology, Novosibirsk, Russian Federation. “Botox injections in the epicardial fat pads have the potential to become standard of care for patients undergoing open heart surgery and provide a new opportunity to reduce AF and associated complications.”

The lead authors call for a large, multi-center study to assess the safety and efficacy of botox injections in the epicardial fat pads for AF prevention and to further showcase the clinical benefit of this technique.

For more information: www.hrsonline.org

Related Content

Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Overlay Init